ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Later, Bedel et al. [11] reported that when CD34BCR-ABL+ cells from CML patients were reprogrammed, CML-iPSCs lost their BCR-ABL dependency and became resistant to tyrosine kinase inhibitor therapy.